Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis

Bone

Volumn 27, Issue 1, 2000, Pages 119-122

  Rossini, M ^a   Gatti, D ^a   Girardello, S ^a   Braga, V ^a   James, G ^a   Adami, S ^a  

^a Ospedale di Valeggio   (Italy)

Author keywords

Alendronate; Cyclic alendronate; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; CALCIUM; COLLAGEN TYPE 1; NERIDRONIC ACID; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG INTERMITTENT THERAPY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK FRACTURE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERTEBRA FRACTURE;

ADMINISTRATION, ORAL; AGED; ALENDRONATE; BONE DENSITY; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; TREATMENT OUTCOME;

EID: 0034129990     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(00)00291-X     Document Type: Article

References (26)

1. Adami S., Baroni M.C., Bordini M., Carratelli L., Caruso I., Gnessi L., Laurenzi M., Lombardi A., Norbiato G., Ortolani S., Ricerca E., Romanini L., Subrizi S., Weimberg J., Yates A.J. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin. Osteopor Int. 3:(Suppl.):1993;21-27.
2. Adami S., Zamberlan N. Adverse effects of bisphosphonates A comparative review. Drug Safety. 14:1996;158-170.
3. Balena R., Toolan B.C., Shea M., Markatos A., Myers E.R., Lee S.C., Opas E.E., Seedor J.G., Klein H., Frankenfield D., Quartuccio H., Fioravanti C., Clair J., Brown E., Hayes W.D., Rodan G.A. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest. 92:1993;2677-2686.
4. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., Bauer D.C., Genant H.K., Haskell W.L., Marcus R., Ott S.M., Torner J.C., Quandt S.A., Reiss T.F., Ensrud K.E. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 348:1996;1535-1541.
5. Bone H.G., Downs R.W., Tucci J.R., Harris S.T., Weinstein R.S., Licata A.A., McClung M.R., Kimmel D.B., Gertz B.J., Hale E., Polvino W.J. Dose-response relationships for alendronate treatment in osteoporotic elderly women. J Clin Endocrinol Metab. 82:1997;265-274.
6. Chesnut C.H. III, Harris S.T. Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women. Osteopor Int. 3:(Suppl.):1993;17-19.
7. Chesnut C.H., McClung M.R., Ensrud K.E., et al. Alendronate treatment of the postmenopausal osteoporotic woman Effect of multiple dosages on bone mass and bone remodeling. Am J Med. 99:1995;144-152.
8. Consensus Development Conference. Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646-650; 1993.
9. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., Palermo L., Prineas R., Rubin S.M., Scott J.C., Vogt T., Wallace R., Yates A.J., LaCroix A.Z. Effect of Alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA. 280:1998;2077-2082.
10. Ericksen E.F., Gundersen H.J.G., Melsen F., Mosekilde L. Reconstruction of the formative site in iliac trabecular bone in 20 normal individuals employing a kinetic model for matrix and mineral apposition. Metab Bone Dis Rel Res. 5:1984;243-252.
11. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., Christiansen C., Delmas P.D., Zanchetta J.R., Stakkestad J., Glüer C.C., Krueger K., Cohen F.J., Eckert S., Ensrud K.E., Avioli L.V., Lips P., Cummings S.R. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA. 282:1999;637-645.
12. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., Chesnut C.H., Brown J., Eriksen E.F., Hoseyni M.S., Axelrod D.W., Miller P.D. Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA. 282:1999;1344-1352.
13. Harris S.T., Watts N.B., Jackson R.D., Genant H.K., Wasnich R.D., Ross P., Miller P.D., Licata A.A., Chesnut C.H. III. Four-year study of intermittent cyclical etidronate treatment of postmenopausal osteoporosis Three years of blinded therapy followed by one year of open therapy. Am J Med. 95:1993;557-567.
14. Hosking D., Chilvers C.E.D., Christiansen C., Ravn P., Wasnich R., Ross P., McClung M., Balske A., Thompson D., Daley M., Yates A.J. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med. 338:1998;485-492.
15. Loocker A.C., Wahner H.W., Dunn W.L., Calvo M.S., Harris T.B., Heyse S.P., Johnston C.C. Jr, Lindsay R. Updated data on proximal femur bone mineral levels of US adults. Osteopor Int. 8:1998;468-489.
16. Kanis J.A., Delmas P., Burckardt P., Cooper C., Torgerson D. Guidelines for diagnosis and management of osteoporosis. Osteopor Int. 7:1997;390-406.
17. Liberman U.A., Wiss S.R., Broll J., Minne H.W., Quan H., Bell N.H., Rodriquez-Portales J., Downs R.W., Dequeker J., Favus M., Seeman E., Recker R.R., Capizzi T., Santora A.C., Lombardi A., Shah R.V., Hirsch L.J., Karpf D.B. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 333:1995;1437-1443.
18. Lin J.H., Russell G., Gertz B. Pharmacokinetics of alendronate An overview. Int J Clin Pract. 100:(Suppl):1999;18-26.
19. McClung M., Clemmesen B., Daifotis A., Gilchrist N.L., Eisman J., Weinstein R.S., Fuleihan G.E.H., Reda C., Yates A.J., Ravn P. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Ann Intern Med. 128:1998;253-261.
20. National Osteoporosis Foundation. Analyses of the effectiveness and cost of screening and treatment strategies for osteoporosis: A basis for development of practice guidelines. Osteopor Int 8(Suppl.):1-88; 1998.
21. Passeri M., Baroni M.C., Pedrazzoni M., Pioli G., Barbagallo M., Costi D., Biondi M., Girasole G., Arlunno B., Palummeri E. Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone Miner. 15:1991;237-248.
22. Pols H.A.P., Felsenberg D., Hanley D.A., et al. Multinational, placeb-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass Results of the FOSIT study. Osteopor Int. 9:1999;461-468.
23. Rossini M., Gatti D., Zamberlan N., Braga V., Dorizzi R., Adami S. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res. 9:1994;1833-1837.
24. Seedor J.G., Quartuccio H.A., Thompson D.D. The bisphosphonate alendronate inhibits bone loss due to ovariectomy in rats. J Bone Miner Res. 6:1991;339-346.
25. Storm T., Thamsborg G., Steiniche T., Genant H.K., Sorensen O.H. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med. 322:1990;1265-1271.
26. Toolan B.C., Shea M., Myers E.R., Borchers R.E., Seedor J.G., Quartuccio H., Rodan G., Hayes W.C. Effects of 4-amino-1-hydroxy-butylidene bisphosphonate on bone biomechanics in rats. J Bone Miner Res. 7:1992;1399-1406.